Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
The Lancet (British edition), 2020-07, Vol.396 (10246), p.e6-e7
2020

Details

Autor(en) / Beteiligte
Titel
Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers
Ist Teil von
  • The Lancet (British edition), 2020-07, Vol.396 (10246), p.e6-e7
Ort / Verlag
England: Elsevier Ltd
Erscheinungsjahr
2020
Link zum Volltext
Quelle
MEDLINE
Beschreibungen/Notizen
  • Health-care workers (HCWs) are at high risk of developing COVID-19, and may themselves contribute to transmission.1 To evaluate these risks, we enrolled 200 patient-facing HCWs between March 26 and April 8, 2020, in SARS-CoV-2 Acquisition in Frontline Healthcare Workers—Evaluation to inform Response (SAFER), a prospective cohort study in high-risk frontline HCWs in an acute National Health Service hospital trust in London. Of the 42 HCWs that ever tested positive for SARS-CoV-2 by RT-PCR, 20 (48%) reported symptoms within 7 days of the positive test that were consistent with Public Health England's COVID-19 case definition,2 and 16 (38%) did not report any symptoms in the same time frame. CS is funded by a Royal Society Napier Professorship, the Rosetrees Trust, and the Breast Cancer Research Foundation; receives grant support from Pfizer, AstraZeneca, BMS, Roche-Ventana, Boehringer Ingelheim, and Ono Pharmaceutical; has consulted for Pfizer, Novartis, GlaxoSmithKline, MSD, BMS, Celgene, AstraZeneca, Illumina, Genentech, Roche-Ventana, GRAIL, Medicxi, and the Sarah Cannon Research Institute; is a shareholder of Apogen Biotechnologies, Epic Bioscience, and GRAIL; and has stock options in and is co-founder of Achilles Therapeutics.

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX